PlainRecalls
FDA Drug Moderate Class II Terminated

Rifampin Capsules, USP, 150 mg, 30-count bottle, Rx only, Manufactured by Patheon Pharmaceuticals Inc., OH, Packaged by GSMS, Incorporated, CA, NDC 51407-322-30

Reported: October 26, 2022 Initiated: October 6, 2022 #D-0012-2023

Product Description

Rifampin Capsules, USP, 150 mg, 30-count bottle, Rx only, Manufactured by Patheon Pharmaceuticals Inc., OH, Packaged by GSMS, Incorporated, CA, NDC 51407-322-30

Reason for Recall

Failed impurities/degradation specifications: Finished product exceeds the 5 ppm interim limit for 1-Methyl-4-Nitrosopoperazine (MNP).

Details

Units Affected
N/A
Distribution
USA nationwide
Location
Camarillo, CA

Frequently Asked Questions

What product was recalled?
Rifampin Capsules, USP, 150 mg, 30-count bottle, Rx only, Manufactured by Patheon Pharmaceuticals Inc., OH, Packaged by GSMS, Incorporated, CA, NDC 51407-322-30. Recalled by Golden State Medical Supply Inc.. Units affected: N/A.
Why was this product recalled?
Failed impurities/degradation specifications: Finished product exceeds the 5 ppm interim limit for 1-Methyl-4-Nitrosopoperazine (MNP).
Which agency issued this recall?
This recall was issued by the FDA Drug on October 26, 2022. Severity: Moderate. Recall number: D-0012-2023.